Amylin Pharmaceuticals Inc. can (finally) put another check in the win column, with the FDA's approval of Bydureon, a once-weekly version of exenatide, a move that puts the San Diego-based biotech on solid footing for a lucrative ex-U.S. partnering deal – even a potential buyout isn't out of the question.